The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke.

Hdl Handle:
The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke.
Sandercock, P; Lindley, R; Wardlaw, J; Dennis, M; Lewis, S; Venables, G; Kobayashi, A; Czlonkowska, A; Berge, E; Slot, KB; Murray, V; Peeters, A; Hankey, G; Matz, K; Brainin, M; Ricci, S; Celani, MG; Righetti, E; Cantisani, T; Gubitz, G; Phillips, S; Arauz, A; Prasad, K; Correia, M; Lyrer, P
Trials 2008, 9 (1):37
Additional Links:

Full metadata record

DC FieldValue Language
dc.contributor.authorSandercock, P-
dc.contributor.authorLindley, R-
dc.contributor.authorWardlaw, J-
dc.contributor.authorDennis, M-
dc.contributor.authorLewis, S-
dc.contributor.authorVenables, G-
dc.contributor.authorKobayashi, A-
dc.contributor.authorCzlonkowska, A-
dc.contributor.authorBerge, E-
dc.contributor.authorSlot, KB-
dc.contributor.authorMurray, V-
dc.contributor.authorPeeters, A-
dc.contributor.authorHankey, G-
dc.contributor.authorMatz, K-
dc.contributor.authorBrainin, M-
dc.contributor.authorRicci, S-
dc.contributor.authorCelani, MG-
dc.contributor.authorRighetti, E-
dc.contributor.authorCantisani, T-
dc.contributor.authorGubitz, G-
dc.contributor.authorPhillips, S-
dc.contributor.authorArauz, A-
dc.contributor.authorPrasad, K-
dc.contributor.authorCorreia, M-
dc.contributor.authorLyrer, P-
dc.identifier.citationTrials 2008, 9 (1):37en
dc.description.abstractABSTRACT: BACKGROUND: Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for use in selected patients with ischaemic stroke within 3 hours of symptom onset. IST-3 seeks to determine whether a wider range of patients may benefit. DESIGN: International, multi-centre, prospective, randomized, open, blinded endpoint (PROBE) trial of intravenous rt-PA in acute ischaemic stroke. Suitable patients must be assessed and able to start treatment within 6 hours of developing symptoms, and brain imaging must have excluded intracerebral haemorrhage. With 1000 patients, the trial can detect a 7% absolute difference in the primary outcome. With3500 patients, it can detect a 4.0% absolute benefit & with 6000, (mostly treated between 3 & 6 hours), it can detect a 3% benefit. TRIAL PROCEDURES: Patients are entered into the trial by telephoning a fast, secure computerised central randomisation system or via a secure web interface. Repeat brain imaging must be performed at 24-48 hours. The scans are reviewed 'blind' by expert readers. The primary measure of outcome is the proportion of patients alive and independent (Modified Rankin 0-2) at six months (assessed via a postal questionnaire mailed directly to the patient). Secondary outcomes include: events within 7 days (death, recurrent stroke, symptomatic intracranial haemorrhage), outcome at six months (death, functional status, EuroQol). TRIAL REGISTRATION: ISRCTN25765518.en
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Kardiologi: 771en
dc.titleThe third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke.en
dc.typepeer revieweden
dc.contributor.departmentThe IST-3 Co-ordinating Centre, Neurosciences Trials Unit, Bramwell Dott Building, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK.
dc.contributor.departmentUllevaal University Hospitalen

Related articles on PubMed

All Items in HeRA are protected by copyright, with all rights reserved, unless otherwise indicated.